BKK:KLINIQ-F (Thailand)
Â
Alien Market
฿
41.5
(0%)
Jul 20
Business Description
The Klinique Medical Clinic PCL
Share Class Description:
BKK:KLINIQ-F: Alien MarketDescription
The Klinique Medical Clinic PCL provides skin care services, beauty, skin care, body contouring, and surgery. including providing holistic care services. The company has a wide range of services and products to meet the needs of customers at all levels, such as facial treatment services, reducing redness, reducing dark spots, laser services for face lifting, face reshaping, skin care, Body shape by removing and dissolving fat, cosmetic surgery, etc. In addition, the company also sells cosmeceuticals. There are various types of products, such as Special Care, Clean & Prepare, Whitening Set, Sun Care, and Antioxidant. The group operates two core business segments: Skin medical services and distribution of cosmetics and medical cosmetics; and Surgery services.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.42 |
N/A
|
N/A
| |||
Equity-to-Asset | 0.53 |
N/A
|
N/A
| |||
Debt-to-Equity | 0.35 |
N/A
|
N/A
| |||
Debt-to-EBITDA | 0.74 |
N/A
|
N/A
| |||
Interest Coverage | 19.54 |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.05 | |||||
Beneish M-Score | -2.87 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 18.7 | |||||
3-Year EBITDA Growth Rate | 16.6 |
N/A
|
N/A
| |||
3-Year EPS without NRI Growth Rate | 10.9 |
N/A
|
N/A
| |||
3-Year FCF Growth Rate | 15.2 |
N/A
|
N/A
| |||
3-Year Book Growth Rate | 2.5 |
N/A
|
N/A
|
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.27 |
N/A
|
N/A
| |||
Quick Ratio | 0.93 |
N/A
|
N/A
| |||
Cash Ratio | 0.81 |
N/A
|
N/A
| |||
Days Inventory | 66.52 |
N/A
|
N/A
| |||
Days Sales Outstanding | 1.21 |
N/A
|
N/A
| |||
Days Payable | 32.35 |
N/A
|
N/A
|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | 4.55 |
N/A
|
N/A
|
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 50.76 |
N/A
|
N/A
| |||
Operating Margin % | 13.77 |
N/A
|
N/A
| |||
Net Margin % | 10.45 |
N/A
|
N/A
| |||
EBITDA Margin % | 23.01 |
N/A
|
N/A
| |||
FCF Margin % | 11.49 |
N/A
|
N/A
| |||
OCF Margin % | 19.33 |
N/A
|
N/A
| |||
ROE % | 22.55 |
N/A
|
N/A
| |||
ROA % | 12.14 |
N/A
|
N/A
| |||
ROIC % | 15.72 |
N/A
|
N/A
| |||
3-Year ROIIC % | 12.2 |
N/A
|
N/A
| |||
ROC (Joel Greenblatt) % | 29.62 |
N/A
|
N/A
| |||
ROCE % | 23.24 |
N/A
|
N/A
| |||
Years of Profitability over Past 10-Year | 6 |
N/A
|
N/A
|
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 15.25 |
N/A
|
N/A
| |||
Forward PE Ratio | 23.81 |
N/A
|
N/A
| |||
PE Ratio without NRI | 15.25 |
N/A
|
N/A
| |||
Price-to-Owner-Earnings | 6.33 |
N/A
|
N/A
| |||
PEG Ratio | 0.72 |
N/A
|
N/A
| |||
PS Ratio | 1.59 |
N/A
|
N/A
| |||
PB Ratio | 3.22 |
N/A
|
N/A
| |||
Price-to-Tangible-Book | 3.23 |
N/A
|
N/A
| |||
Price-to-Free-Cash-Flow | 13.88 |
N/A
|
N/A
| |||
Price-to-Operating-Cash-Flow | 8.25 |
N/A
|
N/A
| |||
EV-to-EBIT | 10.99 |
N/A
|
N/A
| |||
EV-to-EBITDA | 6.69 |
N/A
|
N/A
| |||
EV-to-Revenue | 1.54 |
N/A
|
N/A
| |||
EV-to-FCF | 13.28 |
N/A
|
N/A
| |||
Price-to-GF-Value | 0.62 |
N/A
|
N/A
| |||
Price-to-Peter-Lynch-Fair-Value | 0.79 |
N/A
|
N/A
| |||
Price-to-Graham-Number | 1.48 |
N/A
|
N/A
| |||
Earnings Yield (Greenblatt) % | 9.09 |
N/A
|
N/A
| |||
FCF Yield % | 7.15 |
N/A
|
N/A
|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
The Klinique Medical Clinic PCL Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ฿) | 3,828.79 | ||
| EPS (TTM) (฿) | 1.82 | ||
| Beta | 0.01 | ||
| 3-Year Sharpe Ratio | -61.75 | ||
| 3-Year Sortino Ratio | -3.46 | ||
| Volatility % | 2.36 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (฿) | - | ||
| 20-Day SMA (฿) | 41.5 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (฿) | 41.5 - 41.5 | ||
| Shares Outstanding (Mil) | 220 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
The Klinique Medical Clinic PCL Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
The Klinique Medical Clinic PCL Stock Events
| Event | Date | Price (฿) | ||
|---|---|---|---|---|
| THB 0.750000 Cash Dividend | 2026-04-29 | 41.50 (+0.00%) | ||
| THB 0.700000 Cash Dividend | 2025-08-26 | 41.50 (+0.00%) | ||
| THB 0.750000 Cash Dividend | 2025-04-29 | 41.50 (+0.00%) | ||
| THB 0.650000 Cash Dividend | 2024-08-29 | 41.50 (+0.00%) |
Show
Entries
The Klinique Medical Clinic PCL Frequently Asked Questions
What is The Klinique Medical Clinic PCL(BKK:KLINIQ-F)'s stock price today?
The current price of BKK:KLINIQ-F is ฿41.50. The 52 week high of BKK:KLINIQ-F is ฿41.50 and 52 week low is ฿41.50.
When is next earnings date of The Klinique Medical Clinic PCL(BKK:KLINIQ-F)?
The next earnings date of The Klinique Medical Clinic PCL(BKK:KLINIQ-F) is .
Does The Klinique Medical Clinic PCL(BKK:KLINIQ-F) pay dividends? If so, how much?
The Klinique Medical Clinic PCL(BKK:KLINIQ-F) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on The Klinique Medical Clinic PCL
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers